Tenaya Therapeutics, Inc. (TNYA)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
0.86 USD
+0.03
(3.359%)
⇧
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:09 a.m. EDT
Tenaya Therapeutics presents a stark dichotomy between a distressed balance sheet and a speculative catalyst-driven rally. Fundamentally, the company is in severe trouble: it has burned through nearly 90% of its value over the last three years, carries a massive debt load relative to its tiny equity base, and generates no revenue while posting significant losses. The negative earnings per share and lack of dividends confirm this is not a value play. However, the short-term outlook is buoyed entirely by external validation. Analysts have recently upgraded their targets to $4.00 following positive interim data for its TN-401 drug candidate, which has already pushed the stock up significantly in the last week. This creates a high-risk, high-reward environment suitable only for traders betting on the next clinical milestone, not investors seeking business quality. The options market reflects this perfectly, with heavy call buying at strikes far above the current price, treating the stock as a potential moonshot rather than a stable asset. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.101783 |
| MSTL | 0.103010 |
| AutoTheta | 0.113079 |
| AutoETS | 0.117934 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.013 |
| Excess Kurtosis | 0.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.527 |
| Revenue per Share | 0.001 |
| Market Cap | 187,617,232 |
| Forward P/E | -2.09 |
| Beta | 2.84 |
| Website | https://www.tenayatherapeutics.com |
As of July 11, 2026, 3:09 a.m. EDT: Speculators are positioning for a binary event rather than a trend. Call volume is heavily skewed toward out-of-the-money strikes ($1.50 and $2.00) expiring in late 2026 and early 2027, suggesting bets on a massive price surge driven by clinical data or regulatory milestones. Conversely, put writing is concentrated at lower strikes ($0.50), indicating a defined floor for downside protection. The implied volatility gap between near-term and far-dated options suggests the market prices in a 'lottery ticket' scenario where the stock either doubles on a catalyst or fades back to zero.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19972265 |
| Address1 | 171 Oyster Point Boulevard |
| Address2 | Suite 500 |
| All Time High | 32.0 |
| All Time Low | 0.36 |
| Ask | 1.07 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 3,316,500 |
| Average Daily Volume3 Month | 3,730,691 |
| Average Volume | 3,730,691 |
| Average Volume10Days | 3,316,500 |
| Beta | 2.837 |
| Bid | 0.6008 |
| Bid Size | 2 |
| Book Value | 0.489 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8646 |
| Current Ratio | 5.754 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.8649 |
| Day Low | 0.82 |
| Debt To Equity | 9.527 |
| Display Name | Tenaya Therapeutics |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -78,320,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.492 |
| Enterprise To Revenue | 519.321 |
| Enterprise Value | 116,847,232 |
| Eps Current Year | -0.3825 |
| Eps Forward | -0.414 |
| Eps Trailing Twelve Months | -0.44 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.7963 |
| Fifty Day Average Change | 0.06830001 |
| Fifty Day Average Change Percent | 0.0857717 |
| Fifty Two Week Change Percent | 19.972265 |
| Fifty Two Week High | 2.35 |
| Fifty Two Week High Change | -1.4854 |
| Fifty Two Week High Change Percent | -0.63208514 |
| Fifty Two Week Low | 0.532 |
| Fifty Two Week Low Change | 0.3326 |
| Fifty Two Week Low Change Percent | 0.62518793 |
| Fifty Two Week Range | 0.532 - 2.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 216,072,291 |
| Forward Eps | -0.414 |
| Forward P E | -2.0884058 |
| Free Cashflow | -41,898,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 70 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 225,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00466 |
| Held Percent Institutions | 0.48362 |
| Implied Shares Outstanding | 216,998,877 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. |
| Long Name | Tenaya Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 187,617,232 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_409125654 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -83,005,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 187,617,228 |
| Number Of Analyst Opinions | 6 |
| Open | 0.8313 |
| Operating Cashflow | -64,386,000 |
| Operating Margins | -89.17778 |
| Payout Ratio | 0.0 |
| Phone | 650 825 6990 |
| Pre Market Change | -0.0016000271 |
| Pre Market Change Percent | -0.1850598 |
| Pre Market Price | 0.863 |
| Pre Market Time | 1,784,115,939 |
| Previous Close | 0.8365 |
| Price Eps Current Year | -2.2603922 |
| Price Hint | 4 |
| Price To Book | 1.7680982 |
| Price To Sales Trailing12 Months | 833.8544 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.453 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.028100014 |
| Regular Market Change Percent | 3.3592365 |
| Regular Market Day High | 0.8649 |
| Regular Market Day Low | 0.82 |
| Regular Market Day Range | 0.82 - 0.8649 |
| Regular Market Open | 0.8313 |
| Regular Market Previous Close | 0.8365 |
| Regular Market Price | 0.8646 |
| Regular Market Time | 1,784,059,200 |
| Regular Market Volume | 1,890,621 |
| Return On Assets | -0.38464 |
| Return On Equity | -0.73591006 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 216,998,876 |
| Shares Percent Shares Out | 0.120900005 |
| Shares Short | 26,232,552 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 29,295,482 |
| Short Name | Tenaya Therapeutics, Inc. |
| Short Percent Of Float | 0.15720001 |
| Short Ratio | 9.42 |
| Source Interval | 15 |
| State | CA |
| Symbol | TNYA |
| Target High Price | 8.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 3.5 |
| Total Cash | 80,887,000 |
| Total Cash Per Share | 0.373 |
| Total Debt | 10,117,000 |
| Total Revenue | 225,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.965525 |
| Two Hundred Day Average Change | -0.10092497 |
| Two Hundred Day Average Change Percent | -0.1045286 |
| Type Disp | Equity |
| Volume | 1,890,621 |
| Website | https://www.tenayatherapeutics.com |
| Zip | 94,080 |